Topics

European approval announced for Astellas' Xospata in FLT3+ treatment-resistant acute myeloid leukaemia http://bit.ly/36aTX31  #pharmapic.twitter.com/KQ03LbbWwO

06:22 EDT 28 Oct 2019 | Pharmafile

European approval announced for Astellas' Xospata in FLT3+ treatment-resistant acute myeloid leukaemia http://bit.ly/36aTX31 

Original Article: European approval announced for Astellas' Xospata in FLT3+ treatment-resistant acute myeloid leukaemia http://bit.ly/36aTX31  #pharmapic.twitter.com/KQ03LbbWwO

NEXT ARTICLE

More From BioPortfolio on "European approval announced for Astellas' Xospata in FLT3+ treatment-resistant acute myeloid leukaemia http://bit.ly/36aTX31  #pharmapic.twitter.com/KQ03LbbWwO"

Quick Search